1. Home
  2. COEP vs CGTX Comparison

COEP vs CGTX Comparison

Compare COEP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • CGTX
  • Stock Information
  • Founded
  • COEP 2017
  • CGTX 2007
  • Country
  • COEP United States
  • CGTX United States
  • Employees
  • COEP N/A
  • CGTX N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • COEP Health Care
  • CGTX Health Care
  • Exchange
  • COEP Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • COEP 32.4M
  • CGTX 30.0M
  • IPO Year
  • COEP N/A
  • CGTX 2021
  • Fundamental
  • Price
  • COEP $11.54
  • CGTX $0.64
  • Analyst Decision
  • COEP
  • CGTX Strong Buy
  • Analyst Count
  • COEP 0
  • CGTX 6
  • Target Price
  • COEP N/A
  • CGTX $8.30
  • AVG Volume (30 Days)
  • COEP 136.7K
  • CGTX 891.3K
  • Earning Date
  • COEP 03-25-2025
  • CGTX 03-25-2025
  • Dividend Yield
  • COEP N/A
  • CGTX N/A
  • EPS Growth
  • COEP N/A
  • CGTX N/A
  • EPS
  • COEP N/A
  • CGTX N/A
  • Revenue
  • COEP N/A
  • CGTX N/A
  • Revenue This Year
  • COEP N/A
  • CGTX N/A
  • Revenue Next Year
  • COEP N/A
  • CGTX N/A
  • P/E Ratio
  • COEP N/A
  • CGTX N/A
  • Revenue Growth
  • COEP N/A
  • CGTX N/A
  • 52 Week Low
  • COEP $2.31
  • CGTX $0.34
  • 52 Week High
  • COEP $13.70
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • COEP 59.40
  • CGTX 43.76
  • Support Level
  • COEP $8.65
  • CGTX $0.60
  • Resistance Level
  • COEP $13.70
  • CGTX $0.82
  • Average True Range (ATR)
  • COEP 2.11
  • CGTX 0.06
  • MACD
  • COEP -0.24
  • CGTX -0.02
  • Stochastic Oscillator
  • COEP 61.22
  • CGTX 18.56

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: